Several modern trials of combinati...

Several modern trials of combination hormone therapy plant that the risk of coronary heart disease (CHD) pat venous thromboembolism, and breast cancer outweighed the benefits of therapy. The estrogen-only (conjugated equine estrogen [CEE]) arm of the Women's Health Initiative trial was allowed to continue until it fall of the curtained in February 2004. A cogitation committee presented the primary issues of the estrogen-only arm of the trial.

Healthy women 50 to 79 years of age who had undergone hysterectomy were randomized to receive 0625 mg of CEE by means of day or placebo. Clinical, laboratory, and radiographic data were assembleed at regular intervals to assess CEE's efficiencys on CHD, venous thromboembolism, fractures, cancer, overall health, and mortality. Women were followed for an average of 68 years. Although no predefined boundaries for termination of the thought had been crossed, the risk of attack almost reached the point of crossing and appeared to be similar to the risk of rap previously reported in the combination arm of the trial. Of the 10176 women with available data, 52 percent withdrew, and 538 percent discontinued medication. most numerous of the discontinuations occurred in the couple groups early in the trial, and the cohort remained stable thereafter.

Significant decreases in low-density lipoprotein flats and increases in high-density lipoprotein flats were noted in the CEE assign places to with mean systolic blood hurry increases of 1.1 mm Hg in the CEE form into groups CHD rates were similar in one as well as the other groups, but stroke incidence was 39 percent higher in the close attention group. Venous thromboembolism was increased at 33 percent in the CEE assemblage Breast cancer was reduced by means of 23 percent compared with placebo, on the contrary this reduction was not statistically significant. Fracture rates also were reduc according to one third. Overall health and mortality were equivalent in the sum of two units groups.

CEE reduc fractures significantly in women with no result on CHD, global health, or overall mortality. A direction toward breast cancer reduction was observ which may have been fit solely to chance (in other trials, no as it is reduction has been observed). However, it appears quite likely that CEE alone does not bear the same adverse breast cancer risk as combination therapy. calamity and venous thromboembolism were increased in women taking estrogen Overall, these findings give little reason for using estrogen therapy for any preventive object The authors conclude that the no other than indication for estrogen therapy is to alleviate menopausal symptoms. In these women estrogen replacement for a period of six to seven years appears to be safe.

efficiencys of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controll Trial. JAMA April 14 2004;291:1701-12

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group